A review of the totality of evidence in the development of ABP 798, a rituximab biosimilar

被引：1
|
作者：
Cobb, Patrick [1 ]
Niederwieser, Dietger [2 ]
Cohen, Stanley [3 ]
Hamm, Caroline [4 ]
Burmester, Gerd [5 ,6 ]
Seo, Neungseon [7 ]
Lehto, Sonya G. [7 ]
Hanes, Vladimir [7 ]
机构：
[1] St Vincent Frontier Canc Ctr, Billings, MT 59102 USA
[2] Univ Leipzig, Div Hematol & Oncol, Liebigstr 19, D-04106 Leipzig, Germany
[3] Metroplex Clin Res Ctr, Dallas, TX 75231 USA
[4] Western Univ Windsor, Windsor Oncol, Windsor, ON N8W 2X3, Canada
[5] Free Univ, Dept Rheumatol & Clin Immunol, Charite Pl 1, D-10117 Berlin, Germany
[6] Humboldt Univ, Charite Univ Med Berlin, Charite Pl 1, D-10117 Berlin, Germany
[7] Amgen Inc, One Amgen Ctr Dr, Thousand Oaks, CA 91320 USA
来源：
IMMUNOTHERAPY | 2022年 / 14卷 / 09期
关键词：
ABP; 798; biologics; biosimilars; non-Hodgkin lymphoma; rheumatoid arthritis; rituximab; ACTIVE RHEUMATOID-ARTHRITIS; FOLLICULAR LYMPHOMA; DOUBLE-BLIND; EFFICACY; SAFETY; TRIAL; METHOTREXATE; HEMATOLOGY; THERAPY;
D O I：
10.2217/imt-2022-0024
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
ABP 798 (RIABNI (TM)) is a biosimilar to rituximab reference product (RP), a monoclonal antibody that targets CD20. Approval of ABP 798 was based on the totality of evidence generated using a stepwise approach which began by showing that it is structurally and functionally similar to rituximab RP. This analytical assessment was followed by a demonstration of pharmacokinetic/pharmacodynamic similarity in patients with rheumatoid arthritis. Comparative clinical efficacy and safety of ABP 798 with rituximab RP was demonstrated as a final step in patients with non-Hodgkin lymphoma and in those with rheumatoid arthritis. Overall, the totality of evidence supported the conclusion that ABP 798 is highly similar to rituximab RP and provided scientific justification for extrapolation to other approved indications of rituximab RP.
引用
收藏
页码：727 / 740
页数：14
相关论文
共 50 条
  • [1] Totality of Scientific Evidence in the Development of ABP 798, a Biosimilar to Rituximab
    Niederwieser, Dietger
    Hamm, Caroline
    Cobb, Patrick
    Thway, Theingi
    Forsyth, Cecily
    Tucci, Alessandra
    Delwail, Vincent
    Hajek, Roman
    Hanes, Vladimir
    BLOOD, 2020, 136
  • [2] A Review of the Totality of Evidence for the Development and Approval of ABP 710 (AVSOLA), an Infliximab Biosimilar
    Walter Reinisch
    Stanley Cohen
    Monica Ramchandani
    Majed Khraishi
    Jennifer Liu
    Vincent Chow
    Janet Franklin
    Jean-Frederic Colombel
    Advances in Therapy, 2022, 39 : 44 - 57
  • [3] A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501
    Richard Markus
    Helen J. McBride
    Monica Ramchandani
    Vincent Chow
    Jennifer Liu
    Dan Mytych
    Gary Fanjiang
    Advances in Therapy, 2019, 36 : 1833 - 1850
  • [4] A Review of the Totality of Evidence for the Development and Approval of ABP 710 (AVSOLA), an Infliximab Biosimilar
    Reinisch, Walter
    Cohen, Stanley
    Ramchandani, Monica
    Khraishi, Majed
    Liu, Jennifer
    Chow, Vincent
    Franklin, Janet
    Colombel, Jean-Frederic
    ADVANCES IN THERAPY, 2022, 39 (01) : 44 - 57
  • [5] A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501
    Markus, Richard
    McBride, Helen J.
    Ramchandani, Monica
    Chow, Vincent
    Liu, Jennifer
    Mytych, Dan
    Fanjiang, Gary
    ADVANCES IN THERAPY, 2019, 36 (08) : 1833 - 1850
  • [6] Functional Similarity of Proposed Biosimilar ABP 798 with Rituximab
    McBride, Helen
    Maher, Gwendolyn
    Sweet, Heather
    Foltz, Ian
    Kuhns, Scott
    BLOOD, 2017, 130
  • [7] Totality of evidence in the development of ABP 215, an approved bevacizumab biosimilar
    Thomas, Michael
    Thatcher, Nick
    Goldschmidt, Jerome
    Ohe, Yuichiro
    McBride, Helen J.
    Hanes, Vladimir
    IMMUNOTHERAPY, 2019, 11 (15) : 1337 - 1351
  • [8] Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab
    Kolberg, Hans-Christian
    Colleoni, Marco
    Santi, Patricia
    Demetriou, Georgia Savva
    Angel Segui-Palmer, Miguel
    Fujiwara, Yasuhiro
    Hurvitz, Sara A.
    Hanes, Vladimir
    TARGETED ONCOLOGY, 2019, 14 (06) : 647 - 656
  • [9] Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab
    Hans-Christian Kolberg
    Marco Colleoni
    Patricia Santi
    Georgia Savva Demetriou
    Miguel Angel Segui-Palmer
    Yasuhiro Fujiwara
    Sara A. Hurvitz
    Vladimir Hanes
    Targeted Oncology, 2019, 14 : 647 - 656
  • [10] DEMONSTRATION OF FUNCTIONAL SIMILARITY OF PROPOSED BIOSIMILAR ABP 798 TO RITUXIMAB
    McBride, H.
    Maher, G.
    Sweet, H.
    Foltz, I.
    Canon, J.
    Kuhns, S.
    HAEMATOLOGICA, 2017, 102 : 741 - 741
12345